Fern M. Anari, MD

Dr. Fern Anari
Request an Appointment

Call 888-369-2427

Request Online

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427
  • Fox Chase - East Norriton
    2701 Dekalb Pike
    East Norriton, PA 19401
    Phone: 888-369-2427

Associate Professor, Department of Hematology/Oncology

Specialties

  • Genitourinary Medical Oncology

Areas of Expertise

Urethral Cancer, Adrenal Tumor, Penile Cancer, Ureteral Cancer, Kidney Cancer, Testicular Cancer, Bladder Cancer, Prostate Cancer

Treatment Focus

Chemotherapy, targeted therapy, immunotherapy, hormone therapy, clinical trials for genitourinary malignancies

Distinctions

Treatment Philosophy

I am a medical oncologist specializing in cancers of the genitourinary tract. A new cancer diagnosis can be both overwhelming and life-changing for patients and their loved ones. As a medical oncologist, it is my privilege to help patients navigate this new world by not only helping them understand their diagnosis and treatment options, but also by providing support and guidance along the way. Every patient has a unique experience, so it is important for me to build a relationship with each person I meet so I can best understand his or her values in order to treat each person as a whole. My patients are my number one priority. It is my mission to make sure any and all questions are answered, and that patients and their families feel comfortable with every decision made throughout their journey. 

At Fox Chase Cancer Center, I am lucky to work as part of a multidisciplinary team alongside other medical oncologists, urologists, radiation oncologists and other cancer specialists, which allows me to provide the highest quality of care in a personalized manner tailored to each patient. Being a part of Fox Chase allows me to offer patients both standard-of-care treatments and new, cutting edge treatment options through clinical trial participation. The field of medical oncology is rapidly evolving and Fox Chase is on the forefront of these exciting changes.     

Educational Background

  • Fellowship, Hematology/Medical Oncology, Fox Chase Cancer Center/Temple University Hospital, Philadelphia, PA
  • Residency, Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
  • MD, Rutgers/Robert Wood Johnson Medical School, New Brunswick, NJ

Certifications

  • American Board of Internal Medicine - Internal Medicine
  • American Board of Internal Medicine - Hematology
  • American Board of Internal Medicine - Medical Oncology

Memberships

  • American Society of Clinical Oncology
  • American Society of Hematology
  • Alpha Omega Alpha Honor Medical Society

Honors & Awards

  • Philadelphia Magazine Top Doctors, 2023-26
  • American Medical Women's Association Glasgow-Rubin Citation for Academic Achievement, 2013
  • Angelo P. Angelides Award for Academic Excellence in Medicine, 2013

 

Selected Publications

  • Winer A, Ghatalia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Deiry WS. Dual checkpoint inhibition with ipilimumab plus nivolumab after progression on sequential PD-1/PDL-1 inhibitors pembrolizumab and atezolizumab in a patient with Lynch Syndrome, metastatic colon and localized urothelial cancer. The Oncologist.
  • Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski LA, Saltzberg PD, Bubes N, Anari F, Kasireddy V, Varshavsky A, Liu Y, Ross E, El-Deiry WS. Clinical use of liquid biopsies to detect actionable driver mutations, guide treatment decisions and monitor disease burden during treatment of 33 metastatic colorectal cancer patients at Fox Chase Cancer Center GI Oncology subspecialty clinic. Frontiers in Oncology. 2019 Jan, 8(1-8).    
  • Anari F, Dotan E. Management of Older Adults with Colorectal Cancer. Hospital Physician Hematology/Oncology Board Review Manual. 2018,13(4):7-22.
  • Anari F, Ramamurthy C, Zibelman M. Impact of Tumor Microenvironment Composition on Therapeutic Responses and Clinical Outcomes in cancer. Future Oncology. 2018 Jun;14(14):1409-1421.
  • Anari F, O’Neill J, Choi W, Chen D, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg R, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas C, Trabulsi E, Smaldone M, Geynisman D, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER. Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. European Urology Oncology. 2018 May;1(1):54-60.

Related Articles